Immix Biopharma Inc./$IMMX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Ticker
$IMMX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
20
ISIN
US45258H1068
Website
IMMX Metrics
BasicAdvanced
$66M
-
-$0.70
0.26
-
Price and volume
Market cap
$66M
Beta
0.26
52-week high
$3.00
52-week low
$1.34
Average daily volume
359K
Financial strength
Current ratio
1.803
Quick ratio
1.711
Long term debt to equity
10.331
Total debt to equity
11.038
Management effectiveness
Return on assets (TTM)
-50.17%
Return on equity (TTM)
-112.34%
Valuation
Price to book
6.88
Price to tangible book (TTM)
6.88
Price to free cash flow (TTM)
-5.281
Growth
Earnings per share change (TTM)
-24.15%
3-year earnings per share growth (CAGR)
-43.73%
IMMX News
AllArticlesVideos
Immix Biopharma Attends FDA CEO Forum in Washington DC
GlobeNewsWire·3 days ago
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
GlobeNewsWire·6 days ago
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immix Biopharma Inc. stock?
Immix Biopharma Inc. (IMMX) has a market cap of $66M as of June 09, 2025.
What is the P/E ratio for Immix Biopharma Inc. stock?
The price to earnings (P/E) ratio for Immix Biopharma Inc. (IMMX) stock is 0 as of June 09, 2025.
Does Immix Biopharma Inc. stock pay dividends?
No, Immix Biopharma Inc. (IMMX) stock does not pay dividends to its shareholders as of June 09, 2025.
When is the next Immix Biopharma Inc. dividend payment date?
Immix Biopharma Inc. (IMMX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immix Biopharma Inc.?
Immix Biopharma Inc. (IMMX) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.